This article is more than 5 years old. Information may no longer be current.

TNF inhibitor use linked with reduced odds of radiographic progression in AS

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

MADRID — Prior use of a tumor necrosis factor inhibitor was associated with reduced odds of radiographic progression among patients with ankylosing spondylitis, according to findings recently presented at the EULAR Annual Congress.

“There was data suggesting that [tumor necrosis factor] TNF therapy might decrease radiographic progression in [ankylosing spondylitis] AS,” Adrian Ciurea, MD, from University Hospital Zurich, said in his presentation.

Researchers assessed 420 patients with ankylosing spondylitis and at least 2 years of clinical and radiographic follow-up. Investigators defined radiographic progression as an increase in at least 2 mean modified ankylosing spondylitis spine score (mSASSS) units during the 2-year follow-up. Investigators found the mSASSS after 2 years was 0.9 units. In addition, prior TNF use was linked with a reduced risk for progression in the next 2 years (odds ratio [OR] = 0.51). The addition of ankylosing spondylitis disease activity score (ASDAS) as a covariate to the model decreased the effect (OR = 0.65). In addition, mSASSS at baseline (OR = 1.06), as well as male gender (OR = 3.01), were linked with an increased risk for progression. — by Will Offit

Reference:

Molnar C, et al. Abstract #OP0189. Presented at: EULAR Annual Congress; June 14-17, 2017; Madrid.

Disclosures: Ciurea reports he is a consultant for AbbVie, Celgene, Eli Lilly, Janssen-Cilag, Merck Sharp & Dohme, Novartis, Pfizer and UCB. Please see the abstract for a list of all other authors’ relevant financial disclosures.